S creening for lipid disorders in childhood and adolescence has been controversial. Although it is well documented that atherosclerotic cardiovascular disease is the number 1 cause of death in the United States and that elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is a major risk factor for the development of disease (1), many issues regarding screening in children remain in question.
Various entities, such as the National Heart, Lung, and Blood Institute; the National Cholesterol Education Program; the American Academy of Pediatrics; and the National Lipid Association and the American Heart Association, have recommended some form of screening for lipid disorders in children (2). However, the U.S. Preventive Services Task Force has found insufficient evidence for or against cholesterol screening in childhood (3) . Clearly, there is a need for more evidence to make the best clinical decisions. to 1 in 500 (7) . This is a range for prevalence that in- More evidence is required to determine the optimal approach to screening for children with FH.
Experience with screening programs such as the one in Slovenia is useful, but well-designed prospective studies to evaluate the screening process will be even more important to provide the needed answers. Pediatric Lipid Screening
